Compare Cytokinetics Inc (CYTK) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Tidewater Inc — how do they compare? Cytokinetics Inc trades at $62.42 (market cap $8.62B), while Tidewater Inc trades at $85.18 (market cap $4.21B). The key difference: Cytokinetics Inc is far larger — about 2× Tidewater Inc's market cap, and Tidewater Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Tidewater Inc for 25 Days on average.
| CYTK | TDW | |
|---|---|---|
Market Cap | $8.62B | $4.21B |
Volume | 2,594,626 | 590,005 |
Sector | Health | Energy |
52-Week High | $87.26 | $100.61 |
52-Week Low | $54.76 | $47.29 |
Typical Hold Time | 19 Days | 25 Days |
Enterprise Value | $8.72B | $4.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
Tidewater (TDW) trades at $83.40, up 1.62% on the day, with a bullish technical signal driven by moving averages. Recent earnings showed a Q2 2026 beat but misses in Q1 and Q2 relative to expectations, while the company completed the Wilson Sons Ultratug acquisition in August 2026, signaling growth initiatives. Key financials include a P/E of 17.18 and net income margin of 18.34% for 2025, though 2026 projections indicate lower revenue and profitability.
The outlook is mixed, with analyst consensus leaning toward a buy rating and a price target of $105.50 offering upside potential, but risks include earnings volatility, competitive pressures in the energy sector, and macroeconomic headwinds affecting day rates and utilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
